Inhaled Nitric Oxide for Pulmonary Hypertension and Bronchopulmonary Dysplasia
Treatment of Delayed Pulmonary Transition in Extremely Preterm Infants & Bronchopulmonary Dysplasia
Sponsor: AdventHealth
Terminated
based on DSMB recommendation at interim analysis
This PHASE1/PHASE2 trial investigates Bronchopulmonary Dysplasia and Pulmonary Hypertension and is currently terminated or withdrawn. AdventHealth leads this study, which shows 12 recorded versions since 2019 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
12 versions recorded-
Feb 2025 — Present [monthly]
Terminated PHASE1/PHASE2
-
Sep 2024 — Feb 2025 [monthly]
Terminated PHASE1/PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Status: Recruiting → Terminated
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 7 earlier versions
-
May 2022 — Jul 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2021 — May 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE1_PHASE2
-
May 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2019 — May 2020 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2019 — Sep 2019 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Aug 2018 — Mar 2019 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AdventHealth
- Mallinckrodt
- Thrasher Research Fund
For direct contact, visit the study record on ClinicalTrials.gov .